



OPEN

Author Correction:

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation

Yen-Ju Chen, Chia-Chi Hsu, Young-Ji Shiao, Hsiang-Tsui Wang, Yu-Li Lo & A. M. Y. Lin

Correction to: *Scientific Reports* <https://doi.org/10.1038/s41598-019-38676-7>, published online 21 February 2019

This Article contains errors in Figure 2 and the accompanying Figure legend.

In panel C, in the bar graph showing Relative protein intensity (arbitrary units) for pEGFR, an asterisk (*) is incorrectly shown in the third bar.

In panel D, the representative blot of pAKT is incorrect. Additionally, a representative blot for AKT is incorrectly shown. Instead, a representative blot for β -Actin should be shown. Finally, in the bar graph showing Relative protein intensity (arbitrary units) for pAKT and pERK, a hash sign (#) is incorrectly shown in the fifth and sixth bar.

In panel E, in the bar graph showing Relative protein intensity (arbitrary units) for pEGFR, a hash sign (#) is omitted in the fourth bar.

In panel F, in the bar graph showing Relative protein intensity (arbitrary units) for pEGFR and pERK, a hash sign (#) is omitted in the seventh bar.

Lastly, in the Figure legend,

“Afatinib blocked OGD-induced EGFR activation and downstream signalings. (A,B) CTX-TNA2 cells were exposed to oxygen-glucose deprivation (OGD) for various durations (3, 6, 12 h). Western blot assay was employed to measure (A) the levels of phospho-EGFR (pEGFR) and total-EGFR (EGFR) as well as (B) phospho-ERK (pERK), total-ERK (ERK), phospho-AKT (pAKT), total-AKT (AKT) and β -Actin. Each lane contained 40 μ g protein for all experiments. Graphs show statistical results of pEGFR and EGFR (A) as well as pERK, ERK, pAKT and AKT (B) from relative optical density of bands on the blots. * $P < 0.05$ in the OGD group compared with the control by t-test. (C,D) CTX-TNA2 cells were exposed to OGD for 12 h. Afatinib (1, 10 nM) was included in the culture medium concomitantly with OGD exposure. (E,F) Primary cultured astrocytes were exposed to OGD for 12 h. Afatinib (10 nM) was included in the culture medium concomitantly with OGD exposure. Graphs show statistical results of pEGFR and EGFR (C,E) as well as pERK, ERK, pAKT and AKT (D,F) from relative optical density of bands on the blots. Values are the mean \pm S.E.M. (n = 3/group). * $P < 0.05$ in the OGD group compared with the control, # $P < 0.05$ in OGD plus afatinib compared with OGD alone by Kruskal-Wallis test and followed by Mann-Whitney U test as post-hoc method.”

should read:

“Afatinib blocked OGD-induced EGFR activation and downstream signalings. (A,B) CTX-TNA2 cells were exposed to oxygen-glucose deprivation (OGD) for various durations (3, 6, 12 h). Western blot assay was employed to measure (A) the levels of phospho-EGFR (pEGFR) and total-EGFR (EGFR) as well as (B) phospho-ERK (pERK), total-ERK (ERK), phospho-AKT (pAKT), total-AKT (AKT) and β -Actin. Each lane contained 40 μ g protein for all experiments. Graphs show statistical results of pEGFR (A) as well as pERK and pAKT (B) from relative optical density of bands on the blots. * $P < 0.05$ in the OGD group compared with the control by t-test. (C,D) CTX-TNA2 cells were exposed to OGD for 12 h. Afatinib (1, 10 nM) was included in the culture medium concomitantly with OGD exposure. (E,F) Primary cultured astrocytes were exposed to OGD for 12 h. Afatinib (10 nM) was included in the culture medium concomitantly with OGD exposure. Graphs show statistical results

Published online: 25 January 2021

of pEGFR (C,E) as well as pERK and pAKT (D,F) from relative optical density of bands on the blots. Values are the mean \pm S.E.M. (n = 3/group). n.a. is not applicable because these experiments were performed only in duplicate (n = 2) and so the comparison was not performed. *P < 0.05 in the OGD group compared with the control, #P < 0.05 in OGD plus afatinib compared with OGD alone by Kruskal-Wallis test and followed by Mann-Whitney U test as post-hoc method.”

The correct Figure 2 appears below as Figure 1.




Figure 1. A corrected version of the original Figure 2. Afatinib blocked OGD-induced EGFR activation and downstream signalings. **(A,B)** CTX-TNA2 cells were exposed to oxygen-glucose deprivation (OGD) for various durations (3, 6, 12 h). Western blot assay was employed to measure **(A)** the levels of phospho-EGFR (pEGFR) and total-EGFR (EGFR) as well as **(B)** phospho-ERK (pERK), total-ERK (ERK), phospho-AKT (pAKT), total-AKT (AKT) and β-Actin. Each lane contained 40 μg protein for all experiments. Graphs show statistical results of pEGFR **(A)** as well as pERK and pAKT **(B)** from relative optical density of bands on the blots. *P < 0.05 in the OGD group compared with the control by t-test. **(C,D)** CTX-TNA2 cells were exposed to OGD for 12 h. Afatinib (1, 10 nM) was included in the culture medium concomitantly with OGD exposure. **(E,F)** Primary cultured astrocytes were exposed to OGD for 12 h. Afatinib (10 nM) was included in the culture medium concomitantly with OGD exposure. Graphs show statistical results of pEGFR **(C,E)** as well as pERK and pAKT **(D,F)** from relative optical density of bands on the blots. Values are the mean ± S.E.M. (n = 3/group). n.a. is not applicable because these experiments were performed only in duplicate (n = 2) and so the comparison was not performed. *P < 0.05 in the OGD group compared with the control, *P < 0.05 in OGD plus afatinib compared with OGD alone by Kruskal-Wallis test and followed by Mann-Whitney U test as post-hoc method.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021